title: Eribulin mesylate in Indian patients: A single center experience.
abstract: BACKGROUND
  Eribulin mesylate is the latest addition in the armamentarium of management of metastatic breast cancer (MBC) with a unique mechanism of action. Although the multicentric EMBRACE trial suggests significant overall survival benefit from this novel drug, its effectiveness in Indian population is yet to be evaluated.
  
  
  METHODS
  Presented here is a single center experience of eight patients who were administered eribulin for MBC. Patients had received a median of 3 prior chemotherapies before eribulin administration. The median dose of eribulin therapy was 5 cycles (range: 2-6 cycles).
  
  
  RESULTS
  The objective response rate was 75% (CR in one and PR in five out of eight patients). Response was seen across all subtypes of patients. Eribulin was well tolerated. No serious adverse events were reported.
  
  
  CONCLUSIONS
  Eribulin conferred good response rates with satisfactory tolerability profile in Indian patients. Its use in earlier lines and in combination with other drugs may achieve deeper and longer responses.
authors.forename: R
authors.initials: R
authors.lastname: Thippeswamy
authors.affiliation: Department of Medical Oncology, HCG Bangalore Institute of Oncology Speciality Centre, Bengaluru, Karnataka, India.
authors.forename: S
authors.initials: S
authors.lastname: Patil
authors.forename: H P
authors.initials: HP
authors.lastname: Shashidara
authors.forename: C T
authors.initials: CT
authors.lastname: Satheesh
authors.forename: H
authors.initials: H
authors.lastname: Vittal
authors.forename: S
authors.initials: S
authors.lastname: Mishra
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005663:Furans / Q000008:administration & dosage*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D000095662:Polyether Polyketides
chemical_list: D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides